Novartis drug Gilenya fails to treat tough type of MS

December 1, 2014 1:40 PM

13 0

Novartis AG, the prominent Swiss pharmaceutical firm stated on Monday that its drug Gilenya did not meet its primary objective in a later stage study. The drug was intended to treat primary progressive multiple sclerosis (PPMS).

Results of the Phase III experiment carried out on 970 individuals revealed that Gilenya, also known by the name of fingolimod, did not demonstrate any major difference to placebo on a combination of debility measures.

Read more

To category page